Trial Profile
Study of amyloid-β positivity tracking the progression from amnestic mild cognitive impairment (MCI) to Alzheimer's Disease (AD) dementia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Oct 2018
Price :
$35
*
At a glance
- Drugs Florbetapir F 18 (Primary)
- Indications Alzheimer's disease
- Focus Diagnostic use
- 01 Oct 2018 New trial record